Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accounts Payables: 2015-2024

Historic Accounts Payables for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $5.5 million.

  • Editas Medicine's Accounts Payables fell 74.68% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 74.68%. This contributed to the annual value of $5.5 million for FY2024, which is 33.57% down from last year.
  • As of FY2024, Editas Medicine's Accounts Payables stood at $5.5 million, which was down 33.57% from $8.3 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's Accounts Payables ranged from a high of $9.5 million in FY2022 and a low of $5.0 million during FY2021.
  • Its 3-year average for Accounts Payables is $7.8 million, with a median of $8.3 million in 2023.
  • As far as peak fluctuations go, Editas Medicine's Accounts Payables surged by 88.34% in 2022, and later plummeted by 33.57% in 2024.
  • Yearly analysis of 5 years shows Editas Medicine's Accounts Payables stood at $6.4 million in 2020, then declined by 21.19% to $5.0 million in 2021, then soared by 88.34% to $9.5 million in 2022, then dropped by 13.06% to $8.3 million in 2023, then tumbled by 33.57% to $5.5 million in 2024.